Rise and shine, everyone, another busy day is on the way. But busy is good, yes? Moreover, the tasks in front of us are made easier by a shiny sun and cool breeze enveloping the Pharmalot campus. This calls for celebratory cup of stimulation — chocolate cherry decadence is on tap — and, as always, we invite you to join us. Remember, no prescription is required. So there is no need to worry about those tiresome deductibles, copays, or rebates. Isn’t that nice? Meanwhile, here are some items of interest. Hope you have a swell day and please do keep in touch …

Eli Lilly (LLY) and AstraZeneca (AZN) ended two late-stage trials of an experimental drug for Alzheimer’s disease after the treatment failed to show any signs of working, adding to a litany of disappointments, Bloomberg News says. Like several others that failed, the drug targeted a protein called amyloid, thought to be a cause of the disease. The class of medicines known as BACE inhibitors operate before amyloid forms into deposits called plaques. Many researchers now believe that administering drugs after amyloid builds up in the brain may come too late to affect Alzheimer’s progress.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • If I may quote – “It is not yet clear, though, whether any drug companies have agreed to cut their prices voluntarily.” And if the ‘voluntary cuts’ will mean any more than ‘the voluntary 10% price caps’ that seem to have both come and gone with the wind. The day after Singapore, we may observe another exercise in ‘wind and optics,’ although without a signing ceremony.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy